Canadian speciality pharmaceutical company Paladin Labs has completed the acquisition of all outstanding common shares of Labopharm.
Labopharm develops novel polymeric, nano-delivery systems for delivery of water-insoluble and poorly bio-available drugs.
Paladin Labs interim president and CEO Mark Beaudet said that, through the addition of established international revenue streams, the acquisition will provide them the opportunity to build upon their existing operational capabilities.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData